The open index of psychedelic research

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.

Cohen J, Parbo P, Ørskov PT +6

Changes in depression symptom network structure following ketamine treatment in treatment-resistant depression.

Curtiss J, Dasari L, Origlio J +12

Physicochemical stability of sufentanil and esketamine containing analgesic mixtures applied for patient-controlled intravenous analgesia.

Yao M, Ma Y, Fang B +3

Drug-induced changes in connectivity to midbrain dopamine cells revealed by rabies monosynaptic tracing

Katrina Bartas, Pieter Derdeyn, Guilian Tian +5

Adolescents’ and Young Adults’ Integration Processes for Extended Difficulties Following Challenging Psychedelic Experiences: A Qualitative Investigation

Barfoot S, Luke D, Robinson OC +1

When Therapy Falls Short: A Qualitative Study of Psychotherapy After Challenging Psychedelic Experiences

Simon G, Tadmor N, Evans J +2

Spatiotemporal dynamics of flow experience: an EEG microstate analysis

Khoshnoud S, Alvarez Igarzabal F, Wittmann M

Effect of ultrasound-guided interscalene brachial plexus block using liposome bupivacaine combined with continuous esketamine infusion on quality of recovery in patients undergoing arthroscopic rotator cuff repair: study protocol for a randomized controlled trial.

Yue J, Wang Q, Tang Q +2

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization.

Yu F Jr, Tafur J, Moreno F +1

Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex.

Acuña A, Billeri F, Totaro V +4

Intranasal Dexmedetomidine Versus Esketamine As Premedication for the Sedation of Pediatric Patients: A Systematic Review and Meta-Analysis.

Ghaly L, Al Nuaimi A, Ragab A +6

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial.

van der Vaart A, LaPratt J, Swartz K +5

Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation

[Ketamine and esketamine in treatment-resistant depression - Pharmacological effects and augmented psychotherapy].

Schüle C, Sobieraj A, Rogg H

Esketamine for major depressive disorder: pharmacokinetics and toxicological considerations.

Vasudeva S, Lovell GFM, Rosenblat JD

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.

Beidas Z, Ragnhildstveit A, Blackman A +8

Systematic Under-Characterization of Psychedelic Compound Classes in Published hERG QSAR Training Data: A Pre-Registered Multi-Family Analysis

On the meaning of ‘plasticity’ in neuroscience and mental health research and its relation to the action of psychedelic therapy

Carhart-Harris R, Zeifman R, Pasquini L +8

<i>N</i>‑Benzyl-Tryptamine Derivatives as Serotonin 5‑HT<sub>2</sub> Receptor Ligands: Synthesis and Structure-Affinity/Activity Relationships.

Martínez-Afani D, Soares BA, Mella-Raipán J +5

Attitudes Toward Psychedelics and Psychedelic-Assisted Therapy (PAT) Among Mental Health Professionals in Poland and Their Associations with Cognitive, Epistemic, and Existential Factors

From monotherapy to sequential models: An updated scoping review on ibogaine's role in treatment for psychiatric disorders.

Sharma P, Kendrick J, Schram J +3

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease.

Calleja-Conde J, Echeverry-Alzate V, Sanz-SanCristobal M +6

Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: A randomized clinical trial.

Zhou Y, Sun W, Fu Y +8